Bifogade filer
PDF
Kurs
-0,55%
Likviditet
0,09 MSEK
Kalender
| Tid* | ||
| 2025-03-13 | 13:30 | Kvartalsrapport 2025-Q3 |
| 2025-01-08 | N/A | Extra Bolagsstämma 2025 |
| 2024-11-28 | - | Kvartalsrapport 2025-Q2 |
| 2024-10-12 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2024-09-16 | - | Kvartalsrapport 2025-Q1 |
| 2024-06-26 | - | Bokslutskommuniké 2024 |
| 2024-03-27 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-21 | - | Kvartalsrapport 2024-Q2 |
| 2023-11-15 | - | Extra Bolagsstämma 2024 |
| 2023-10-27 | - | Årsstämma |
| 2023-10-13 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2023-09-20 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-23 | - | Bokslutskommuniké 2023 |
| 2023-05-09 | - | Extra Bolagsstämma 2023 |
| 2023-03-28 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-21 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-31 | - | Årsstämma |
| 2022-10-14 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2022-09-29 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-29 | - | Bokslutskommuniké 2022 |
| 2022-03-21 | - | Kvartalsrapport 2022-Q3 |
| 2022-03-15 | - | Extra Bolagsstämma 2022 |
| 2021-12-29 | - | Kvartalsrapport 2022-Q2 |
| 2021-10-20 | - | Extra Bolagsstämma 2021 |
| 2021-10-11 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2021-09-29 | - | Kvartalsrapport 2022-Q1 |
| 2021-06-24 | - | Bokslutskommuniké 2021 |
| 2021-03-16 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-14 | - | Kvartalsrapport 2021-Q2 |
| 2020-10-20 | - | Årsstämma |
| 2020-10-15 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2020-09-28 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-25 | - | Bokslutskommuniké 2020 |
| 2020-03-12 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-17 | - | Kvartalsrapport 2020-Q2 |
| 2019-10-16 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2019-10-15 | - | Årsstämma |
| 2018-09-27 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2018-09-26 | - | Årsstämma |
| 2018-06-18 | - | Extra Bolagsstämma 2019 |
| 2018-06-12 | - | Bokslutskommuniké 2018 |
| 2018-03-12 | - | Kvartalsrapport 2018-Q3 |
| 2017-09-26 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2017-09-25 | - | Årsstämma |
| 2017-09-11 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-19 | - | Bokslutskommuniké 2017 |
| 2017-03-13 | - | Kvartalsrapport 2017-Q3 |
| 2017-01-01 | - | Extra Bolagsstämma 2018 |
| 2016-11-30 | - | Kvartalsrapport 2017-Q2 |
| 2016-09-06 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2016-09-05 | - | Årsstämma |
| 2016-09-05 | - | Kvartalsrapport 2017-Q1 |
| 2016-06-13 | - | Bokslutskommuniké 2016 |
| 2016-02-22 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-16 | - | Extra Bolagsstämma 2017 |
| 2015-11-30 | - | Kvartalsrapport 2016-Q2 |
| 2015-09-08 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2015-09-07 | - | Årsstämma |
| 2015-09-07 | - | Kvartalsrapport 2016-Q1 |
| 2015-06-16 | - | Bokslutskommuniké 2015 |
| 2015-03-16 | - | Kvartalsrapport 2015-Q3 |
| 2014-12-01 | - | Kvartalsrapport 2015-Q2 |
| 2014-10-07 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2014-10-06 | - | Årsstämma |
| 2014-10-06 | - | Kvartalsrapport 2015-Q1 |
| 2014-06-30 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB ("PHI" or the "Company") has notified the Company that he, together with closely related parties, follows Altium SA's lead by subscribing for shares in the Company's ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
Peter Egelberg, founding Board Member of PHI, comments
"The lack of robust automation has long limited the use of microscopy in manufacturing environments. Since resigning as CEO, I have gone back to my roots in software development, AI, physics and mathematics to solve this long-standing problem. Together with the PHI development team, I have now spent nearly two years improving HoloMonitor's QPI technology. The results have convinced me that PHI will soon be able to offer unprecedented automation of image-based cell analysis for applications in medical research, biomanufacturing and clinical regenerative medicine, which is bound to attract attention in the life science industry."
Advisors
Navia Corporate Finance AB is the financial advisor and Sole Bookrunner in connection with the rights issue. HWF Advokater AB is the legal advisor. Nordic Issuing AB is the issuing agent.
For more information about the rights issue, please contact:
Navia Corporate Finance AB
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com
For additional information, please contact:
Anders Månsson
E-mail: ir@phiab.com
Web: www.phiab.com - Live cell imaging & analysis